iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Short Interest Down 61.4% in April

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) saw a large drop in short interest in April. As of April 30th, there was short interest totaling 47,511 shares, a drop of 61.4% from the April 15th total of 123,125 shares. Based on an average daily trading volume, of 55,288 shares, the days-to-cover ratio is currently 0.9 days. Approximately 0.9% of the shares of the company are short sold.

iShares Genomics Immunology and Healthcare ETF Stock Down 0.6%

IDNA traded down $0.18 during midday trading on Thursday, hitting $29.62. 22,773 shares of the company traded hands, compared to its average volume of 42,224. The company’s 50-day moving average is $29.57 and its 200 day moving average is $28.20. The firm has a market capitalization of $161.43 million, a PE ratio of 14.76 and a beta of 0.97. iShares Genomics Immunology and Healthcare ETF has a 52 week low of $19.19 and a 52 week high of $31.41.

Institutional Investors Weigh In On iShares Genomics Immunology and Healthcare ETF

Large investors have recently added to or reduced their stakes in the stock. Ameriprise Financial Inc. lifted its holdings in shares of iShares Genomics Immunology and Healthcare ETF by 8.4% during the 3rd quarter. Ameriprise Financial Inc. now owns 71,473 shares of the company’s stock valued at $1,688,000 after buying an additional 5,540 shares during the period. Triumph Capital Management purchased a new stake in iShares Genomics Immunology and Healthcare ETF during the third quarter valued at $35,000. Finally, Portland Global Advisors LLC increased its position in iShares Genomics Immunology and Healthcare ETF by 0.7% during the third quarter. Portland Global Advisors LLC now owns 103,007 shares of the company’s stock valued at $2,432,000 after acquiring an additional 684 shares during the last quarter.

iShares Genomics Immunology and Healthcare ETF Company Profile

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.